Genetic - Medika Life

Advances in CAR T, a remarkable immunotherapy treatment dubbed a “living drug.” This new therapy genetically modifies a patient’s cells to fight cancer, but current research efforts hope to treat autoimmune diseases, organ damage and more.

Lawmaker Takes on Insurance Companies and Gets Personal About His Health

Medika Life - June 9, 2022

California state Senator Scott Wiener shares his life experience bringing home the need to reconsider access to care pathways.

Are Your Patients Asking about Wegovy?

Katherine Saunders, MD - September 20, 2023

Ten common questions about popular anti-obesity medications

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

CATEGORIES

Diabetes Is a Major Risk Factor for Dementia. 115 Million Americans Have Prediabetes.

Health Innovation Has a Friction Problem

The Best Dating Game in Health Innovation Happens Just Off the Main Stage

Treating Rare Diseases: The Challenge of Access

LATEST

TRENDING

Alagille syndrome

Health Possibilities We Can’t Afford to Block

The SERPINA1 Gene, serpin family A member 1

Lupus and its effects on women

BRCA1 and 2: The Breast Cancer Genes

FBN1 gene, fibrillin 1

Marfan Syndrome (MFS)

Loeys-Dietz syndrome (LDS)

Crohn’s Disease. Symptoms, Diagnosis, and Treatment

When It Comes to the Future of HLTH – Life Is Not a Las Vegas Roulette Wheel

EDITORS CHOICE

The SERPINA1 Gene, serpin family A member 1

Teaming Up Two Biotech Winners to Fight Cancer: CRISPR and CAR T

Lawmaker Takes on Insurance Companies and Gets Personal About His Health

Are Your Patients Asking about Wegovy?

CONNECT WITH US ON SOCIAL MEDIA

Compliance

CORPORATE & MEDIA

Popular categories